LLY507: Potent and Selective SMYD2 Inhibitor for Cancer and Fibrosis Research

Executive Summary: LLY507 is a small molecule inhibitor targeting SMYD2 with an IC₅₀ below 15 nM, exhibiting over 100-fold selectivity relative to other methyltransferases (APExBIO). SMYD2 is overexpressed in multiple cancers and implicated in pathological fibrosis, including cisplatin-induced renal fibrosis (Chen et al., 2023). LLY507 binds the substrate peptide pocket of SMYD2, inhibiting monomethylation of p53 at Lys370 and other substrates. The compound acts at submicromolar concentrations in cells, limiting SMYD2-mediated modifications without broadly disrupting global histone methylation. No in vivo or clinical trial data are available, and LLY507 is recommended exclusively for preclinical research.

Biological Rationale

SET and MYND domain-containing protein 2 (SMYD2) is a protein lysine methyltransferase. It catalyzes the monomethylation of lysine residues on both histone (e.g., H3K36, H3K4) and non-histone substrates, including the tumor suppressor p53 at Lys370 (Chen et al., 2023). SMYD2 is overexpressed in several cancers, such as esophageal squamous cell carcinoma, liver, and breast cancers. Elevated SMYD2 expression correlates with poor clinical outcomes. In addition to its role in oncogenesis, SMYD2 contributes to fibrotic responses in chronic kidney disease models. Pharmacological inhibition of SMYD2 reduces epithelial-mesenchymal transition (EMT), fibrosis-related protein expression, and pro-inflammatory cytokine production in preclinical models. Thus, selective inhibition of SMYD2 is a promising strategy for dissecting epigenetic regulation in cancer and fibrosis biology.

Mechanism of Action of LLY507

LLY507 is a cell-active SMYD2 inhibitor for cancer research, designed to block the methyltransferase activity of SMYD2 with high selectivity. The compound binds within the substrate peptide binding pocket of SMYD2, directly preventing transfer of methyl groups to critical lysine residues on substrates such as p53 (APExBIO). LLY507 demonstrates minimal off-target activity against a broad panel of methyltransferases and non-methyltransferase enzymes. In cellular systems, LLY507 reduces methylation of p53 at Lys370 at concentrations below 1 μM, without significantly affecting global histone methylation. This selective inhibition is consistent with SMYD2’s cytoplasmic localization and substrate specificity. The compound's rapid and reversible inhibition enables time-resolved studies of SMYD2 enzymatic activity and downstream signaling pathways.

Evidence & Benchmarks

• LLY507 inhibits SMYD2 enzymatic activity with an IC₅₀ < 15 nM at 25°C in buffer assays (APExBIO).
• Exhibits >100-fold selectivity against other methyltransferases and non-methyltransferase targets at 10 μM concentration (APExBIO).
• Reduces monomethylation of p53-Lys370 in cell lines at submicromolar doses (APExBIO).
• In cisplatin-induced CKD mouse models, LLY507 administration lowered SMYD2 expression, reduced renal fibrosis, and decreased inflammatory cytokine levels (IL-6, TNF-α) (Chen et al., 2023).
• LLY507 does not significantly alter global histone methylation marks (e.g., H3K4, H3K36) at effective cellular concentrations (related review).
• Demonstrated inhibition of proliferation in esophageal, liver, and breast cancer cell lines in a dose-dependent manner (APExBIO).

This article extends prior summaries such as LLY-507: Selective SMYD2 Inhibition for Advanced Cancer by providing updated quantitative benchmarks and explicit discussion of lysine methylation pathway selectivity. For a complementary deep-dive on translational and mechanistic models, see LLY-507: Unraveling the Precision of SMYD2 Inhibition, which focuses on apoptosis and cell-based assay optimization. For practical assay workflows, LLY-507 (SKU B6119): Optimizing SMYD2 Inhibition addresses dosing and data reliability challenges not explored here.

Applications, Limits & Misconceptions

LLY507 is a valuable tool for:

• Dissecting the role of SMYD2 in cancer cell epigenetics and proliferation assays.
• Studying SMYD2-mediated lysine methylation in the context of apoptosis and cell viability assays.
• Investigating mechanisms of renal fibrosis and inflammation in preclinical models.
• Screening for protein-lysine methyltransferase pathway modulation.

Common Pitfalls or Misconceptions

• LLY507 is not suitable for in vivo or clinical applications; no pharmacokinetic or safety data in animals or humans are reported.
• The compound does not globally inhibit all methylation events; its selectivity is toward SMYD2 and does not broadly affect histone marks.
• LLY507 solubility is limited in aqueous buffers; recommended solvents are DMSO (≥57.5 mg/mL) and ethanol (≥54.7 mg/mL).
• It should not be used as a probe for other methyltransferases given its high selectivity.
• LLY507 is not a validated therapeutic; usage is for research only as specified by APExBIO.

Workflow Integration & Parameters

LLY507 (SKU B6119) is provided as a solid with a molecular weight of 574.76 and chemical formula C₃₆H₄₂N₆O (APExBIO). For experimental use:

• Dissolve in DMSO or ethanol to prepare stock solutions; avoid water as the compound is insoluble.
• Typical working concentrations in cell-based assays range from 0.01–10 μM, with submicromolar efficacy documented for p53 methylation inhibition.
• Store at –20°C in desiccated conditions to preserve stability.
• LLY507 is not intended for animal or human administration; use only in research laboratory settings.

For robust results, include appropriate controls for solvent and off-target methyltransferase activity. Consult the product page for batch-specific purity and additional technical data.

Conclusion & Outlook

LLY507 is a next-generation, potent, and selective SMYD2 small molecule inhibitor supplied by APExBIO. It enables precise interrogation of protein-lysine methyltransferase pathways in oncology and fibrosis research. While demonstrating robust selectivity and cell-based efficacy, LLY507 is exclusively validated for in vitro and cellular models. No in vivo, pharmacokinetic, or clinical data are available to date. As epigenetic regulation becomes increasingly central to disease modeling, LLY507 represents a critical research tool for dissecting SMYD2 function, provided its boundaries and application scope are respected. For further reading on mechanistic rationale and translational perspectives, see LLY-507 and the Future of SMYD2 Inhibition: Mechanistic Insights, which complements this article’s focus on assay benchmarks and operational guidance.